ATE102197T1 - Arylthiazolylimidazole als 5ht3-antagonisten. - Google Patents

Arylthiazolylimidazole als 5ht3-antagonisten.

Info

Publication number
ATE102197T1
ATE102197T1 AT90304685T AT90304685T ATE102197T1 AT E102197 T1 ATE102197 T1 AT E102197T1 AT 90304685 T AT90304685 T AT 90304685T AT 90304685 T AT90304685 T AT 90304685T AT E102197 T1 ATE102197 T1 AT E102197T1
Authority
AT
Austria
Prior art keywords
het
mono
antagonists
arylthiazolylimidazole
phenyl
Prior art date
Application number
AT90304685T
Other languages
English (en)
Inventor
Arthur Adam Nagel
James Patrick Rizzi
Terry Jay Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE102197T1 publication Critical patent/ATE102197T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT90304685T 1989-05-09 1990-04-30 Arylthiazolylimidazole als 5ht3-antagonisten. ATE102197T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/349,278 US4914207A (en) 1989-05-09 1989-05-09 Arylthiazolylimidazoles

Publications (1)

Publication Number Publication Date
ATE102197T1 true ATE102197T1 (de) 1994-03-15

Family

ID=23371665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90304685T ATE102197T1 (de) 1989-05-09 1990-04-30 Arylthiazolylimidazole als 5ht3-antagonisten.

Country Status (10)

Country Link
US (1) US4914207A (de)
EP (1) EP0397365B1 (de)
JP (1) JPH0692404B2 (de)
AT (1) ATE102197T1 (de)
CA (1) CA2016181C (de)
DE (1) DE69006907T2 (de)
DK (1) DK0397365T3 (de)
ES (1) ES2062354T3 (de)
FI (1) FI94639C (de)
IE (1) IE62936B1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140034A (en) * 1989-03-14 1992-08-18 Merck Sharp & Dohme Ltd. Five-membered ring systems with bonded imidazolyl ring substituents
JPH07121917B2 (ja) * 1989-07-31 1995-12-25 四国化成工業株式会社 4(5)―チオカルバモイル―イミダゾール化合物及びその合成方法
IL101291A0 (en) * 1991-03-22 1992-11-15 Nippon Soda Co 2-pyridine derivatives,their preparation and their use as fungicides
AU1862395A (en) * 1994-03-10 1995-09-25 Yamanouchi Pharmaceutical Co., Ltd. Novel 2-(imidazolylmethyl)thiazole derivative and medicinal comp osition thereof
US5874452A (en) * 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
AU6013998A (en) * 1996-12-30 1998-07-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6093737A (en) * 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6426356B1 (en) 1998-11-18 2002-07-30 Ortho-Mcneil Pharmaceutical, Inc. Imidazoethyl thiophenes
HU228783B1 (en) * 2001-07-26 2013-05-28 Greenearth Cleaning Dry cleaning apparatus and method capable of utilizing a siloxane solvent
CN1894241A (zh) * 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体-5调节剂的“1,2,4” 噁二唑
AU2007309568A1 (en) * 2006-10-20 2008-05-02 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
US8580730B2 (en) 2009-05-20 2013-11-12 (Inserm) Institut National De La Sante Et De La Recherche Medicale Methods of treating lesional vestibular disorders by administering serotonin 5-HT3 receptor antagonists
ES2432618T3 (es) 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US11332308B2 (en) 2017-08-14 2022-05-17 Gestion Claude Boivin Inc. Mechanical arm system for collecting garbage from a garbage container

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3519637A (en) 1966-12-06 1970-07-07 Hoffmann La Roche 1-(4-thiazolylmethyl)nitroimidazole derivatives
NL7017486A (de) * 1969-12-15 1971-06-17
DE1964995A1 (de) * 1969-12-24 1971-07-01 Bayer Ag N-Benzyltriazole,Verfahren zu ihrer Herstellung und ihre Verwendung zur Regulierung des Pflanzenwachstums
US4468399A (en) * 1981-12-28 1984-08-28 Eli Lilly And Company 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyrimidones
FI74707C (fi) * 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
US4746669A (en) 1985-12-23 1988-05-24 Merck & Co., Inc. Substituted thiazoles as immunoregulants
JPH0725754B2 (ja) * 1986-01-30 1995-03-22 富山化学工業株式会社 新規なチアゾール化合物またはその塩
DE3830240A1 (de) * 1987-10-14 1989-04-27 Bayer Ag Substituierte 1-aryl-1-(thiazol-2-yl)-2-(1,2,4-triazol-1-yl)- und -(imidazol-1-yl)-ethanole, verfahren sowie substituierte 1-aryl-1-(thiazol-2-yl)-2-bromethanole als zwischenprodukte zu ihrer herstellung, und sie enthaltende fungizide und pflanzenwuchsregulierende mittel

Also Published As

Publication number Publication date
EP0397365B1 (de) 1994-03-02
JPH0692404B2 (ja) 1994-11-16
DE69006907T2 (de) 1994-06-09
DK0397365T3 (da) 1994-05-24
CA2016181C (en) 1999-03-23
JPH032180A (ja) 1991-01-08
FI94639B (fi) 1995-06-30
EP0397365A1 (de) 1990-11-14
DE69006907D1 (de) 1994-04-07
IE901665L (en) 1990-11-09
FI902292A0 (fi) 1990-05-08
US4914207A (en) 1990-04-03
FI94639C (fi) 1995-10-10
CA2016181A1 (en) 1990-11-09
IE62936B1 (en) 1995-03-08
ES2062354T3 (es) 1994-12-16

Similar Documents

Publication Publication Date Title
ATE102197T1 (de) Arylthiazolylimidazole als 5ht3-antagonisten.
DE58909248D1 (de) Heterocyclisch substituierte alfa-Aryl-acrylsäureester und Fungizide, die diese Verbindungen enthalten.
ATE116317T1 (de) Chinuclidinderivate.
NO924612D0 (no) Fremgangsmaate for fremstilling av 3-amino-2-aryl-kinuklidiner
DE60011895D1 (de) Heterocyclische subtituierte aminoazacyclische verbindungen mit zentraler nervensystemwirkung
DK152090D0 (da) Piperidylsubstituerede indolderivater
FR2683819B1 (fr) Derives de quinoleine, leur procede de preparation et leur application en therapeutique.
DE69302646D1 (de) Benzimidazolverbindungen als Antibiotika gegen Campylobacter pylon
DE69002384D1 (de) Heterocyclische guanidine als 5ht-3-antagonisten.
ATE149031T1 (de) Pyridinderivate
ATE194338T1 (de) Diphenylthiazolderivate mit antiinflammatorischer aktivität
DE69708484D1 (de) Pyridinderivate,als Arzneimittel zur Behandlung von Geschwüren und als antibakterielle Mittel
DE59206593D1 (de) Verwendung von 2-Iminothiazolidin-4-onderivaten als neuartige Arzneimittelwirkstoffe
ATE56213T1 (de) Substituierte carbonsaeureamide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee